These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33689524)

  • 21. Bayesian adaptive decision-theoretic designs for multi-arm multi-stage clinical trials.
    Bassi A; Berkhof J; de Jong D; van de Ven PM
    Stat Methods Med Res; 2021 Mar; 30(3):717-730. PubMed ID: 33243087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leveraging machine learning: Covariate-adjusted Bayesian adaptive randomization and subgroup discovery in multi-arm survival trials.
    Xiong W; Roy J; Liu H; Hu L
    Contemp Clin Trials; 2024 Jul; 142():107547. PubMed ID: 38688389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An alternative metric for evaluating the potential patient benefit of response-adaptive randomization procedures.
    Proper J; Murray TA
    Biometrics; 2023 Jun; 79(2):1433-1445. PubMed ID: 35394063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response-adaptive randomization for multi-arm clinical trials using the forward looking Gittins index rule.
    Villar SS; Wason J; Bowden J
    Biometrics; 2015 Dec; 71(4):969-78. PubMed ID: 26098023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Doubly adaptive biased coin design to improve Bayesian clinical trials with time-to-event endpoints.
    Cao W; Zhu H; Wang L; Zhang L; Yu J
    Stat Med; 2024 Apr; 43(9):1743-1758. PubMed ID: 38387866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization.
    Brown AR; Gajewski BJ; Aaronson LS; Mudaranthakam DP; Hunt SL; Berry SM; Quintana M; Pasnoor M; Dimachkie MM; Jawdat O; Herbelin L; Barohn RJ
    Trials; 2016 Aug; 17(1):428. PubMed ID: 27577191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Bayesian Design of Adaptive Clinical Trials.
    Giovagnoli A
    Int J Environ Res Public Health; 2021 Jan; 18(2):. PubMed ID: 33435249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bayesian two-stage sequential enrichment design for biomarker-guided phase II trials for anticancer therapies.
    Su L; Chen X; Zhang J; Gao J; Yan F
    Biom J; 2022 Oct; 64(7):1192-1206. PubMed ID: 35578917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adding experimental arms to platform clinical trials: randomization procedures and interim analyses.
    Ventz S; Cellamare M; Parmigiani G; Trippa L
    Biostatistics; 2018 Apr; 19(2):199-215. PubMed ID: 29036330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uncertainty directed factorial clinical trials.
    Kotecha G; Ventz S; Fortini S; Trippa L
    Biostatistics; 2024 Jul; 25(3):833-851. PubMed ID: 38330084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Performance of Fixed-Horizon, Look-Ahead Procedures Compared to Backward Induction in Bayesian Adaptive-Randomization Decision-Theoretic Clinical Trial Design.
    Lipsky AM; Lewis RJ
    Int J Biostat; 2019 Feb; 15(1):. PubMed ID: 30726189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bayesian response adaptive randomization using longitudinal outcomes.
    Hatayama T; Morita S; Sakamaki K
    Pharm Stat; 2015; 14(5):369-76. PubMed ID: 26099995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time-trend impact on treatment estimation in two-arm clinical trials with a binary outcome and Bayesian response adaptive randomization.
    Jiang Y; Zhao W; Durkalski-Mauldin V
    J Biopharm Stat; 2020; 30(1):69-88. PubMed ID: 31017843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequentist operating characteristics of Bayesian optimal designs via simulation.
    Zhang Y; Trippa L; Parmigiani G
    Stat Med; 2019 Sep; 38(21):4026-4039. PubMed ID: 31215685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.
    Zhou X; Liu S; Kim ES; Herbst RS; Lee JJ
    Clin Trials; 2008; 5(3):181-93. PubMed ID: 18559407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing a Bayesian hierarchical adaptive platform trial design for stroke patients.
    Gao G; Gajewski BJ; Wick J; Beall J; Saver JL; Meinzer C;
    Trials; 2022 Sep; 23(1):754. PubMed ID: 36068547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adaptive allocation for binary outcomes using decreasingly informative priors.
    Sabo RT
    J Biopharm Stat; 2014; 24(3):569-78. PubMed ID: 24697793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity.
    Lei X; Yuan Y; Yin G
    Lifetime Data Anal; 2011 Jan; 17(1):156-74. PubMed ID: 20364321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial.
    Cellamare M; Milstein M; Ventz S; Baudin E; Trippa L; Mitnick CD
    Int J Tuberc Lung Dis; 2016 Dec; 20(12):8-12. PubMed ID: 28240566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective.
    Arjas E; Gasbarra D
    BMC Med Res Methodol; 2022 Feb; 22(1):50. PubMed ID: 35184731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.